Sol-Gel Technologies ( (SLGL) ) has provided an announcement.
On April 17, 2025, Sol-Gel Technologies announced a product purchase agreement with Mayne Pharma for the U.S. rights to EPSOLAY and TWYNEO, receiving $16 million in 2025. This deal extends Sol-Gel’s cash runway into 2027, supporting the Phase III trial of SGT-610, a potential treatment for Gorlin syndrome, with an estimated U.S. market potential of $400 to $500 million annually. The agreement is expected to enhance Sol-Gel’s financial position and support its clinical programs, while the company continues to establish a commercial network for these products outside the U.S.
Spark’s Take on SLGL Stock
According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.
Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.
To see Spark’s full report on SLGL stock, click here.
More about Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on developing and commercializing drug products for skin diseases. The company has developed TWYNEO, approved for acne vulgaris, and EPSOLAY, approved for rosacea. Their pipeline includes SGT-610 for Gorlin syndrome and SGT-210 for rare skin keratodermas.
YTD Price Performance: -52.94%
Average Trading Volume: 55,979
Technical Sentiment Signal: Buy
Current Market Cap: $13.93M
See more data about SLGL stock on TipRanks’ Stock Analysis page.